Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan

Hirokazu Urushiyama1, Taisuke Jo1-2, Wakae Hasegawa1, Akira Yokoyama1, Takahiro Ando1, Yukio Sakamoto1, Ryosuke Kumazawa1, Kazuaki Uda3, Nobuaki Michihata1, Nobuyasu Awano4, Matsui Hiroki3, Kiyohide Fushimi5, Hideo Yasunaga3 and Takahide Nagase1

1Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 2Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 3Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. 4Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan. 5Department of Health Policy and Informatics, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Corresponding author: Taisuke Jo (jo-taisuke@umin.ac.jp)

Shareable abstract (@ERSpublications)
Initiation of nintedanib during acute exacerbation in patients with fibrosing interstitial lung diseases was significantly associated with lower in-hospital mortality in a Japanese nationwide cohort, adjusted using overlap propensity score weighting https://bit.ly/3RWL4B6

Cite this article as: Urushiyama H, Jo T, Hasegawa W, et al. Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan. ERJ Open Res 2022; 8: 00209-2022 [DOI: 10.1183/23120541.00209-2022].

Abstract

Background Acute exacerbation is a life-threatening event in patients with fibrosing interstitial lung diseases (ILDs). Although nintedanib reduces acute exacerbation incidence, its effectiveness during acute exacerbation is unclear.

Methods Using data from the Diagnosis Procedure Combination database (September 2015–March 2020) in Japan, we identified patients with fibrosing ILDs who received intravenous injection of high-dose corticosteroid within 3 days post-admission and analysed their first hospitalisation. We performed overlap propensity score weighting to compare in-hospital outcomes between patients who received nintedanib within 14 days post-admission and those who did not. The primary and secondary outcomes were in-hospital mortality and length of hospitalisation in the patients discharged alive, respectively.

Results Among the 6235 identified patients, 353 patients received nintedanib within 14 days post-admission. In-hospital mortality occurred in 13.7% and 6.0% patients in the control (n=5882) and nintedanib-treated (n=353) patients, respectively. The mean length of hospitalisation was 39.9 and 30.4 days in the control and nintedanib-treated patients, respectively. After overlap propensity score weighting, nintedanib treatment was significantly associated with lower in-hospital mortality in the adjusted cohort (OR 0.43, 95% CI 0.27–0.70; p=0.001). The mean length of hospitalisation in nintedanib-treated patients (30.7 days) was significantly shorter than that in the control group (37.5 days; p<0.001).

Conclusions Nintedanib initiation during acute exacerbation was significantly associated with a lower risk of in-hospital death and shorter length of hospitalisation in patients with fibrosing ILDs. Our results elucidate the potential role of nintedanib in the treatment of acute exacerbation in patients with fibrosing ILDs. Further prospective studies are warranted.

Introduction

Acute exacerbation is a life-threatening event in patients with idiopathic pulmonary fibrosis (IPF) [1]. Acute exacerbations reportedly occur in IPF and in a wide range of fibrosing interstitial lung diseases (ILDs) [2].

Earlier studies suggested that nintedanib could reduce the incidence of acute exacerbations in fibrosing ILDs [3]. Recently, nintedanib was reported to inhibit IPF and fibrosing ILD progression, regardless of the
aetiology, and was prescribed to various patients with pulmonary fibrosis, under the disease concept of progressive fibrosing ILDs [4]. Thus, nintedanib is considered a key drug for treating fibrosing ILDs.

Considering acute exacerbation treatment, high-dose corticosteroids have been used empirically, particularly in Japan [5]. However, the effectiveness of high-dose corticosteroid has not been demonstrated [6]; thus, establishing an effective treatment for acute exacerbation in fibrosing ILDs is warranted. A recent survey reported that 67% of clinical pulmonologists initiated antifibrotic therapies as treatment for acute exacerbation in patients who had not previously received antifibrotic therapy [7]. However, the effectiveness of antifibrotic therapy for acute exacerbation in fibrosing ILDs, in contrast to its effectiveness in inhibiting acute exacerbation onset, has not been elucidated.

In this study, we examined the effectiveness of nintedanib initiation during the treatment of acute exacerbation in patients with fibrosing ILDs using a nationwide inpatient database in Japan.

Materials and methods

Data source
We conducted a retrospective cohort study using the Diagnosis Procedure Combination database [8], which is a national inpatient database in Japan. The database includes data on patient sex, age, body height and weight (body mass index), Charlson Comorbidity Index [9], smoking history (pack-years), Hugh-Jones dyspnoea scale scores [10], activities of daily living scores (Barthel index) [11], dates of admission and discharge, main diagnoses, comorbidities on admission, medications, information on assisted ventilation, and discharge status. The data of approximately 300 hospitals are combined with the outpatient data on the treatments and prescriptions.

This study was approved by the Institutional Review Board of The University of Tokyo (Tokyo, Japan). The review board waived the requirement for informed consent owing to the use of anonymised data.

Patient selection
As nintedanib has been commercially available in Japan since September 2015, we collected data on patients who were admitted for the treatment of fibrosing ILDs, defined by International Classification of Diseases, 10th Revision (ICD-10) codes J841 and J848–J849, between September 2015 and March 2020. As the ICD-10 codes do not include specific codes for IPF, patients with IPF were further extracted using the diagnosis for IPF recorded in Japanese text. As high-dose corticosteroid intravenous injection treatment (i.e. 500 or 1000 mg methylprednisolone per day) is most commonly used for acute exacerbation treatment in Japan [5], we defined the onset of acute exacerbation as the receipt of this corticosteroid therapy within 3 days after admission. By using this definition, we expected to procure a homogenous patient population considering the severity of acute exacerbation in fibrosing ILDs. The first hospitalisation requiring corticosteroid therapy during the observation period was defined as the index hospitalisation and was analysed for each patient. For adjustment purposes, to evaluate the medications patients received before the index hospitalisation, we excluded patients who did not visit the hospital within 90 days prior to the index hospitalisation. We also excluded patients who received nintedanib prior to the index hospitalisation. Those who received pirfenidone, another antifibrotic drug, during the index hospitalisation were excluded in order to focus on the effect of nintedanib.

Patients who received mechanical ventilation with tracheal intubation or those who did not receive oral corticosteroids within 14 days following admission were also excluded. To account for immortal time bias, we excluded patients who died or were discharged within 14 days after admission. We defined patients who received nintedanib for the first time within 14 days after the index hospitalisation as the nintedanib group and the other patients as the control group.

Covariates
To evaluate the differences in background patient characteristics, we compared the control and nintedanib groups using the following covariates at admission: sex, age, body mass index (categorised according to World Health Organization definitions into underweight (<18.5 kg·m$^{-2}$), normal weight (18.5–24.9 kg·m$^{-2}$), overweight (25.0–29.9 kg·m$^{-2}$) and obese (≥30.0 kg·m$^{-2}$)), Charlson Comorbidity Index, smoking history (pack-years), severity of respiratory condition (Hugh-Jones dyspnoea scale), activities of daily living scores (Barthel index: fully independent (100), independent (60–95) and dependent (0–55)), date of admission, prescriptions of oral corticosteroid and pirfenidone prior to the index hospitalisation, main diagnoses (IPF or not), comorbidities on admission identified by recorded ICD-10 codes (respiratory failure (J96), bacterial pneumonia (J13–J18), COPDs (J41–J44), pneumothorax (J93), heart disease (I20–I25, I50, I110), liver disease (B15–B19, K70–K77), gastro-oesophageal reflux disease (GORD) (K21),
cancer (C00–C97), bronchial asthma (J45–J46), hypertension (I10–I13, I15), diabetes mellitus (E10–E14), thyroid diseases (E03–E06) and osteoporosis (M80–M82), mean number of days from admission to i.v. injection of high-dose corticosteroid, use of noninvasive positive pressure ventilation, and mean number of admissions at the index hospitalisation.

**Study outcomes**
The primary outcome of this study was in-hospital death. The secondary outcome was the length of hospital stay in patients who were discharged alive.

**Statistical analysis**
Propensity score analysis can effectively adjust for measured confounders and is most commonly used to balance patient backgrounds between the two groups (treated and untreated) in retrospective studies [12]. The propensity score is defined as the probability of assigning an individual to the treatment group. In the present study, propensity scores for receiving nintedanib treatment were calculated using a multivariable logistic regression model containing all the aforementioned covariates. To attain adequate balance between bias and variance, we performed overlap propensity score weighting [13]. Overlap propensity score weights were defined as 1 minus the propensity scores for the nintedanib group and the propensity scores for the control group. Overlap propensity score weighting achieves an exact balance in measured variables and an accurate estimation of the association between treatment and outcome compared with conventional propensity score methods such as matching or inverse probability weighting [14]. The created patient population mimics the cohort of a randomised control trial without excluding patients from the original cohort. Baseline characteristics were compared between the two groups using the standardised mean difference before and after weighting, with an absolute standardised difference of <0.1 considered to denote a negligible difference in covariates [15]. In-hospital mortality was compared between the two groups using Fisher’s exact test. Overlap propensity score-weighted logistic regression analyses were performed to estimate the odds ratio of in-hospital death and the 95% confidence interval between the two groups. Length of hospital stay was also analysed via linear regression analyses. All statistical analyses were performed using Stata version 17.0 (StataCorp, College Station, TX, USA). A two-tailed significance level of 0.05 was used in all statistical analyses.

**Subgroup and sensitivity analyses**
We conducted subgroup analyses restricted to patients with IPF or non-IPF. Four sensitivity analyses were also conducted. For the first sensitivity analysis, we included patients with fibrosing ILDs who received an i.v. injection of high-dose corticosteroid within 10 days, instead of the 3 days in the main analysis, as those with acute exacerbation. For two other sensitivity analyses, we used an alternative definition of the

![Graphical summary of the main and sensitivity analyses](https://doi.org/10.1183/23120541.00209-2022)

**FIGURE 1** Graphical summary of the main and sensitivity analyses. a) Initiation periods of nintedanib and i.v. high-dose corticosteroid therapy in the main analysis. b) Change from 3 days to 10 days after admission of i.v. injection of high-dose corticosteroid for the definition of acute exacerbation. c) Change from 14 days to 7 days or 10 days after admission for the definition of the nintedanib group.
“nintedanib group” (i.e. the prescription of nintedanib within 7 days and 10 days after admission, instead of the 14 days in the main analysis). Thus, we examined the therapeutic effect of nintedanib using four combinations of the definition of acute exacerbation in fibrosing ILDs and the nintedanib group.

For the fourth sensitivity analysis, we excluded patients with sepsis, acute respiratory distress syndrome and pneumonias which are specifically diagnosed, treated and usually severe (e.g. pneumocystis pneumonia, Legionella pneumonia, cytomegalovirus pneumonia, Pseudomonas aeruginosa pneumonia and methicillin-resistant Staphylococcus aureus (MRSA) pneumonia) at admission before calculating propensity scores. In real-world practice, distinguishing these diseases from acute exacerbation of fibrosing ILDs could be challenging. A graphical summary of the sensitivity analyses is shown in figure 1.

Results

Patient characteristics

We identified 6235 eligible patients with fibrosing ILDs who required high-dose corticosteroid therapy within 3 days after hospitalisation. Among these, 353 patients newly received nintedanib within 14 days after hospitalisation (the nintedanib group); the other 5882 patients were defined as the control group. A flow diagram of the study is shown in figure 2.

The baseline characteristics of the eligible patients are shown in table 1. More patients in the nintedanib group than in the control group were aged \( \geq 75 \) years, obese (BMI \( \geq 30.0 \) kg·m\(^{-2}\)), heavy smokers (pack-years: 41–60 and \( \geq 61 \)), had received pirfenidone, and were admitted between April 2018 and March 2019. The control group had higher proportions of individuals aged 65–74 years, with Charlson Comorbidity Index \( \geq 2 \), smoking history of never and \( \leq 20 \) pack-years, Hugh-Jones dyspnoea scale score of 4, fully independent and independent status in activities of daily living, admission between April 2016 and March 2017, and mean number of admissions at the index hospitalisation. These imbalances in baseline characteristics between the two groups were corrected after the overlap propensity score weighting. The C-statistic in the propensity score model was 0.89.

Comorbidities on admission and the treatment of eligible patients are shown in table 2. More patients in the nintedanib group than in the control group had IPF, bacterial pneumonia, COPD, heart disease and...
More patients in the control group than in the nintedanib group had liver disease, cancer, diabetes mellitus, osteoporosis and thyroid diseases. The mean number of days from admission to i.v. injection of high-dose corticosteroid was higher in the control group. These imbalances in comorbidities on admission and during treatment between the two groups were corrected after the overlap propensity score weighting.

**Outcomes**

In-hospital death and length of hospital stay are shown in table 3. In the original cohort, in-hospital mortality was lower in the nintedanib group (6.0%) than in the control group (13.7%; $p<0.001$). The mean±SD length of hospital stay in patients who were discharged alive was shorter in the nintedanib group (30.4±12.6 days) than in the control group (39.9±22.2 days; $p<0.001$). After adjusting the cohort using

| TABLE 1 Baseline characteristics of eligible patients in the original and adjusted cohorts |
|-----------------------------------------------|-----------------------------------------------|
| **Original cohort** | **Adjusted cohort** |
| | Control group (n=5882) | Nintedanib group (n=353) | Control group (n=3118) | Nintedanib group (n=3118) |
| Male | 4149 (70.5) | 258 (73.1) | 0.06 | 2382 (76.4) | 2382 (76.4) | 0.00 |
| Age (years) | | | | | | |
| <65 | 1013 (17.2) | 53 (15.0) | | 577 (18.5) | 577 (18.5) | 0.00 |
| 65–74 | 2192 (37.3) | 90 (25.5) | −0.26 | 870 (27.9) | 870 (27.9) | 0.00 |
| >75 | 2677 (45.5) | 210 (59.5) | 0.28 | 1670 (53.6) | 1670 (53.6) | 0.00 |
| BMI (kg·m$^{-2}$) | | | | | | |
| <18.5 | 665 (11.3) | 46 (13.0) | 0.05 | 353 (11.3) | 353 (11.3) | 0.00 |
| 18.5–24.9 | 3415 (58.1) | 206 (58.4) | 0.06 | 1762 (56.5) | 1762 (56.5) | 0.00 |
| 25.0–29.9 | 1388 (23.6) | 75 (21.3) | −0.06 | 697 (22.4) | 697 (22.4) | 0.00 |
| >30.0 | 127 (2.2) | 19 (5.4) | 0.17 | 219 (7.0) | 219 (7.0) | 0.00 |
| Missing | 287 (4.9) | 7 (2.0) | −0.16 | 87 (2.8) | 87 (2.8) | 0.00 |
| CCI | | | | | | |
| 0–1 | 2500 (42.5) | 140 (39.7) | −0.06 | 1311 (42.0) | 1311 (42.0) | 0.00 |
| >2 | 2051 (34.9) | 96 (27.2) | −0.17 | 869 (27.9) | 869 (27.9) | 0.00 |
| Missing | 1331 (22.6) | 117 (33.1) | 0.24 | 937 (30.1) | 937 (30.1) | 0.00 |
| Smoking history (pack-years) | | | | | | |
| Never | 2471 (42.0) | 77 (21.8) | −0.44 | 718 (23.0) | 718 (23.0) | 0.00 |
| ≤20 | 628 (10.7) | 21 (5.9) | −0.17 | 244 (7.8) | 244 (7.8) | 0.00 |
| 21–40 | 1090 (18.5) | 63 (17.8) | −0.02 | 608 (19.5) | 608 (19.5) | 0.00 |
| 41–60 | 615 (10.5) | 50 (14.2) | 0.11 | 411 (13.2) | 411 (13.2) | 0.00 |
| >61 | 534 (9.1) | 55 (15.6) | 0.03 | 515 (16.5) | 515 (16.5) | 0.00 |
| Missing | 544 (9.2) | 41 (11.6) | 0.08 | 295 (9.5) | 295 (9.5) | 0.00 |
| Hugh-Jones dyspnoea scale | | | | | | |
| 1 | 540 (9.2) | 36 (10.2) | 0.03 | 392 (12.6) | 392 (12.6) | 0.00 |
| 2 | 655 (11.1) | 40 (11.3) | 0.01 | 335 (10.8) | 335 (10.8) | 0.00 |
| 3 | 864 (14.7) | 55 (15.6) | 0.03 | 515 (16.5) | 515 (16.5) | 0.00 |
| 4 | 1279 (21.7) | 52 (14.7) | −0.18 | 544 (17.4) | 544 (17.4) | 0.00 |
| 5 | 1489 (25.3) | 101 (28.6) | 0.07 | 868 (27.9) | 868 (27.9) | 0.00 |
| Missing | 1055 (17.9) | 69 (19.5) | 0.04 | 463 (14.9) | 463 (14.9) | 0.00 |
| ADL score (Barthel index) | | | | | | |
| Fully independent | 2653 (45.1) | 124 (35.1) | −0.21 | 1133 (36.3) | 1133 (36.3) | 0.00 |
| Independent | 827 (14.1) | 20 (5.7) | −0.28 | 242 (7.8) | 242 (7.8) | 0.00 |
| Dependent | 1546 (26.3) | 91 (25.8) | −0.01 | 782 (25.1) | 782 (25.1) | 0.00 |
| Missing | 856 (14.6) | 118 (33.4) | 0.45 | 960 (30.8) | 960 (30.8) | 0.00 |
| Preceding pirfenidone | 389 (6.6) | 38 (10.8) | 0.15 | 311 (10.0) | 310 (10.0) | 0.00 |
| Preceding OCS | 948 (16.1) | 32 (9.1) | −0.21 | 356 (11.4) | 356 (11.4) | 0.00 |
| Admission year | | | | | | |
| September 2015–March 2016 | 650 (11.1) | 35 (9.9) | −0.04 | 283 (9.1) | 283 (9.1) | 0.00 |
| April 2016–March 2017 | 964 (16.4) | 29 (8.2) | −0.25 | 288 (9.2) | 288 (9.2) | 0.00 |
| April 2017–March 2018 | 1288 (21.9) | 89 (25.2) | 0.08 | 817 (26.2) | 817 (26.2) | 0.00 |
| April 2018–March 2019 | 1701 (28.9) | 120 (34.0) | 0.11 | 1044 (33.5) | 1044 (33.5) | 0.00 |
| April 2019–March 2020 | 1279 (21.7) | 80 (22.7) | 0.02 | 686 (22.0) | 686 (22.0) | 0.00 |
| Admissions (n) | 11.2±16.9 | 8.6±6.4 | −0.20 | 8.5±10.7 | 8.5±6.2 | 0.00 |

Data are presented as n (%) or mean±sd, unless otherwise stated. SMD: standardised mean difference; BMI: body mass index; CCI: Charlson Comorbidity Index; ADL: activities of daily living; OCS: oral corticosteroid.
overlap propensity score weighting, in-hospital mortality was lower in the nintedanib group (7.1%) than in the control group (15.1%; \( p < 0.001 \)). The mean±SD length of hospital stay in patients who were discharged alive was shorter in the nintedanib group (30.7±13.7 days) than in the control group (37.5±19.0 days; \( p < 0.001 \)). Logistic regression analyses in the adjusted cohort showed that the odds ratio of in-hospital death in the nintedanib group was 0.43 (95% CI 0.27–0.70; \( p = 0.001 \)).

For subgroup analysis, the adjusted cohort was divided into IPF patients or non-IPF patients. In patients with IPF, the in-hospital mortality was lower in the nintedanib group (8.9%) than in the control group (14.0%; \( p = 0.001 \)). Logistic regression analyses showed that the odds ratio of in-hospital death in the nintedanib group was 0.60 (95% CI 0.35–1.03; \( p = 0.062 \)). In non-IPF patients, the in-hospital mortality was also lower in the nintedanib group (2.8%) than in the control group (17.7%; \( p < 0.001 \)). Logistic regression analyses showed that the odds ratio of in-hospital death in the nintedanib group was 0.13 (95% CI 0.03–0.56; \( p = 0.006 \)).

In-hospital deaths of the three sensitivity analyses based on the different definitions of acute exacerbation in fibrosing ILDs and the nintedanib group are shown in table 4. First, we changed the definition of acute

| TABLE 2 Comorbidities and treatment of eligible patients in the original and adjusted cohorts |
|----------------------------------------|-----------------|-----------------|-----------------|------------------|-----------------|------------------|
| Comorbidities                          | Original cohort | Adjusted cohort |
|                                       | Control group   | Nintedanib group | SMD  | Control group | Nintedanib group | SMD  |
| IPF                                    | 1941 (33.0)     | 277 (78.5)       | 1.03 | 2207 (70.8)   | 2207 (70.8)       | 0.00 |
| Respiratory failure                    | 2255 (38.3)     | 139 (39.4)       | 0.02 | 1240 (39.8)   | 1240 (39.8)       | 0.00 |
| Bacterial pneumonia                    | 618 (10.5)      | 59 (16.7)        | 0.18 | 463 (14.8)    | 463 (14.8)        | 0.00 |
| COPD                                   | 876 (14.9)      | 77 (21.8)        | 0.18 | 622 (20.0)    | 622 (20.0)        | 0.00 |
| Pneumothorax                           | 50 (0.9)        | 2 (0.6)          | −0.03| 26 (0.8)      | 26 (0.8)          | 0.00 |
| Heart disease                          | 826 (14.0)      | 64 (18.1)        | 0.11 | 468 (15.0)    | 468 (15.0)        | 0.00 |
| Liver disease                          | 321 (5.5)       | 9 (2.6)          | −0.15| 115 (3.7)     | 115 (3.7)         | 0.00 |
| GORD                                   | 1264 (21.5)     | 107 (30.3)       | 0.20 | 900 (28.9)    | 900 (28.9)        | 0.00 |
| Cancer                                 | 896 (15.2)      | 36 (10.2)        | −0.15| 388 (12.4)    | 388 (12.4)        | 0.00 |
| Bronchial asthma                       | 344 (5.9)       | 20 (5.7)         | −0.01| 255 (8.2)     | 255 (8.2)         | 0.00 |
| Hypertension                           | 1389 (23.6)     | 74 (21.0)        | −0.06| 647 (20.8)    | 647 (20.8)        | 0.00 |
| Diabetes mellitus                      | 2199 (37.4)     | 86 (24.4)        | −0.29| 885 (28.4)    | 885 (28.4)        | 0.00 |
| Osteoporosis                           | 834 (14.2)      | 21 (6.0)         | −0.28| 244 (7.8)     | 244 (7.8)         | 0.00 |
| Thyroid diseases                       | 151 (2.6)       | 4 (1.1)          | −0.11| 50 (1.6)      | 50 (1.6)          | 0.00 |
| Treatment                              |                |                 |     |                |                 |      |
| Time from admission to high-dose i.v.  | 1.41±0.67       | 1.25±0.62        | −0.25| 1.29±0.56      | 1.29±0.65         | 0.00 |
| corticosteroid therapy (days)          | 871 (14.8)      | 56 (15.9)        | 0.03 | 479 (15.4)    | 479 (15.4)        | 0.00 |

Data are presented as n (%) or mean±SD, unless otherwise stated. SMD: standardised mean difference; IPF: idiopathic pulmonary fibrosis; GORD: gastro-oesophageal reflux disease; NPPV: noninvasive positive pressure ventilation.

TABLE 3 Outcomes with or without nintedanib in the original and adjusted cohorts

|                      | Original cohort | Adjusted cohort |
|----------------------|-----------------|-----------------|
|                      | Control group   | Nintedanib group | p-value | Control group | Nintedanib group | p-value |
| In-hospital death    | 804 (13.7)      | 21 (6.0)        | <0.001 | 471 (15.1)    | 222 (7.1)        | <0.001 |
| Length of hospital stay (days) | 39.9±22.2 | 30.4±12.6 | <0.001 | 37.5±19.0 | 30.7±13.7 | <0.001 |

Data are presented as n (%) or mean±SD, unless otherwise stated. After overlap propensity score weighting, nintedanib treatment was significantly associated with lower in-hospital mortality in the adjusted cohort (OR 0.43, 95% CI 0.27–0.70; \( p = 0.001 \)).
exacerbation by altering the period of i.v. injection of high-dose corticosteroid from 3 days after admission (in the main analysis) to 10 days. The odds ratio of in-hospital death in the nintedanib group was 0.67 (95% CI 0.45–0.97; p=0.036), after the overlap propensity score weighting (n=4000 patients in each group). Next, we changed the period used for the definition of the nintedanib group from 14 days to 7 days (n=2262 patients) or 10 days (n=2476 patients) after admission. After overlap propensity score weighting, the odds ratios of in-hospital death in the nintedanib group were 0.63 (95% CI 0.34–1.19; p=0.157) and 0.40 (95% CI 0.22–0.73; p=0.003) for 7 and 10 days after admission, respectively.

In the fourth sensitivity analysis, we found and excluded patients with sepsis (n=51 patients), acute respiratory distress syndrome (n=44 patients), pneumocystis pneumonia (n=95 patients), Legionella pneumonia (n=3 patients), cytomegalovirus pneumonia (n=69 patients), P. aeruginosa pneumonia (n=2 patients) and MRSA pneumonia (n=0 patients) at admission using ICD-10 codes. After excluding these patients, we recalculated the propensity scores for receiving nintedanib treatment and performed overlap propensity score weighting. In this adjusted cohort, the in-hospital mortality was lower in the nintedanib group (7.2%) than in the control group (14.8%; p<0.001). Logistic regression analyses in the adjusted cohort showed that the odds ratio of in-hospital death in the nintedanib group was 0.45 (95% CI 0.28–0.73; p=0.001).

**Discussion**

This study showed that in an overlap propensity score weighting-adjusted cohort, the use of nintedanib within 14 days after admission was significantly associated with a lower risk of in-hospital death and a shorter length of hospital stay in patients with fibrosing ILDs who received i.v. injection of high-dose corticosteroid. To the best of our knowledge, this study provides the first evidence regarding the therapeutic effect of nintedanib during the treatment of acute exacerbation in patients with fibrosing ILDs in a nationwide clinical setting.

Poor outcomes of acute exacerbation of IPF and fibrosing ILDs are an urgent clinical problem [16]. Although no randomised controlled trials on corticosteroid treatment in acute exacerbation of fibrosing ILDs are available, high-dose corticosteroids are recommended in the management guidelines of acute exacerbation of IPF [1, 5] and a review of acute exacerbation of fibrosing ILDs [17], and are frequently used in the real-world to treat acute exacerbation of fibrosing ILDs. However, the evidence of the treatment of acute exacerbations of IPF and fibrosing ILDs has not been well established. Until now, the benefits of corticosteroid [6], cyclophosphamide [18] and thrombomodulin alfa [19] have not been evident in patients with acute exacerbations of IPF. Although nintedanib reportedly reduced the risk of acute exacerbations of IPF [20] and fibrosing ILDs [3], the role of nintedanib during acute exacerbation in patients with ILDs has not been studied. Our study is consistent with a previous study which utilised propensity score matching analyses and showed that the use of antifibrotic treatment, such as nintedanib and pirfenidone therapies, before the onset of acute exacerbation was associated with a lower rate of mortality attributed to acute exacerbation in patients with IPF [21]. However, our study is different from the aforementioned study for the following reasons: 1) patients with fibrosing ILDs other than IPF were included in the present study, 2) all patients in the current study were most likely first-time users of high-dose corticosteroid therapy, 3) nintedanib was prescribed only after hospitalisation for acute exacerbation in our cohort and 4) nintedanib was prescribed during acute exacerbation treatment in our patients. In this way, our study showed for the first time that the use of nintedanib during acute exacerbation was significantly associated with a lower mortality rate in patients with fibrosing ILDs, including IPF.

To confirm the robustness of the main results, we conducted several sensitivity analyses using different definitions for acute exacerbation in patients with fibrosing ILDs and for the nintedanib group (i.e. the date of i.v. injection of high-dose corticosteroid and the date of prescription of nintedanib). Acute exacerbation may exhibit a variable clinical course: some patients may have presented with severe respiratory failure at admission and were treated immediately with an i.v. injection of high-dose corticosteroid, while others may have presented with relatively mild respiratory failure at admission but subsequently experienced

---

**TABLE 4** Sensitivity analyses for in-hospital death in the adjusted cohorts

| High-dose corticosteroid | Nintedanib initiation | Patients in each group (n) | OR (95% CI) | p-value |
|--------------------------|-----------------------|---------------------------|-------------|---------|
| Within 10 days           | Within 14 days        | 4000                      | 0.67 (0.45–0.97) | 0.036   |
| Within 3 days            | Within 7 days         | 2262                      | 0.63 (0.34–1.19) | 0.157   |
|                          | Within 10 days        | 2476                      | 0.40 (0.22–0.73) | 0.003   |

https://doi.org/10.1183/23120541.00209-2022
deteriorated respiratory conditions during hospitalisation. Patients who required i.v. injection of high-dose corticosteroid within 3 days may have mostly included the former group of patients, whereas patients who required i.v. injection of high-dose corticosteroid within 10 days after admission may have mostly included the latter group. Because the results were similar in both settings, nintedanib therapy may be beneficial in patients with acute exacerbation regardless of their clinical course. Moreover, in our sensitivity analyses, we evaluated two earlier time-points of starting nintedanib (i.e. 7 and 10 days after admission) in addition to the 14 days after admission in the main analysis. Nintedanib reduced the risk of in-hospital death in patients with acute exacerbation of fibrosing ILDs when it was started within all three time-points. Therefore, nintedanib may be effective when it is started as soon as the patient is capable of receiving oral medication.

Other clinical questions include whether there is a difference in the mortality of acute exacerbation and the efficacy of nintedanib between IPF and non-IPF patients. In our adjusted cohort, there was no difference in the mortality of acute exacerbation between patients with IPF and non-IPF. The use of nintedanib was associated with a lower risk of in-hospital death in patients restricted to the IPF or non-IPF groups.

In real-world practice, sepsis, acute respiratory distress syndrome and pneumonias, such as pneumocystis pneumonia, *Legionella* pneumonia, cytomegalovirus pneumonia, *P. aeruginosa* pneumonia and MRSA pneumonia, at admission are usually severe, and distinguishing these from acute exacerbation of fibrosing ILDs could be challenging. In the adjusted cohort that excluded these patients, the use of nintedanib was significantly associated with a lower risk of in-hospital death.

This study had some limitations. First, the Diagnosis Procedure Combination database does not contain imaging examination findings (e.g. chest radiography and chest computed tomography) or patients’ respiratory status. In this study, i.v. injection of high-dose corticosteroid was used as a proxy for acute exacerbation onset. Our definition of acute exacerbation in patients with fibrotic ILDs may not fully capture the onset of acute exacerbation in patients with fibrotic ILDs, especially in those with mild acute exacerbation who did not receive i.v. injection of high-dose corticosteroid. Second, the results of this study may not be applicable to patients who died, were discharged or received mechanical ventilation with tracheal intubation 7 days after admission. These patients were excluded to account for immortal time bias in our sensitivity analyses, which used the prescription of nintedanib within 7 days after admission for the definition of the nintedanib group.

In conclusion, this study showed that the use of nintedanib during the treatment of acute exacerbation was significantly associated with a lower risk of in-hospital death and a shorter length of hospital stay in patients with fibrosing ILDs, after adjustments using overlap propensity score weighting. Our results elucidate the potential role of nintedanib in the treatment of acute exacerbation in patients with fibrosing ILDs. Further prospective studies are required.

Provenance: Submitted article, peer reviewed.

Author contributions: H. Urushiyama, T. Jo and H. Yasunaga conceived and designed the study, analysed and interpreted data, and wrote the manuscript; W. Hasegawa, A. Yokoyama, T. Ando, Y. Sakamoto, R. Kumazawa, K. Uda, N. Michihata, N. Awano, M. Hiroki and K. Fushimi collected and analysed data, and gave final approval of the manuscript; and T. Nagase conceived and designed the study, and gave final approval of the manuscript.

Conflict of interest: All authors declare no conflicts of interest related to this study.

Support statement: This work was funded by grants from the Ministry of Health, Labour and Welfare, Japan (H30-Policy-Designated-001, H30-Policy-Designated-004 and H29-ICT-General-004), and the Ministry of Education, Culture, Sports, Science and Technology, Japan (17H04141). The funding bodies had no role in the design of the study, the collection, analysis or interpretation of data, or the writing of the manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.

References

1. Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. *Am J Respir Crit Care Med* 2016; 194: 265–275.

2. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. *N Engl J Med* 2019; 381: 1718–1727.
3 Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J 2021; 59: 2004538.

4 Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases – subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8: 453–460.

5 Homma S, Bando M, Azuma A, et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig 2018; 56: 268–291.

6 Farrand E, Vittinghoff E, Ley B, et al. Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. Respirology 2020; 25: 629–635.

7 Kreuter M, Polke M, Walsh SLF, et al. Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur Respir J 2020; 55: 1901760.

8 Yasunaga H, Matsui H, Horiguchi H, et al. Clinical epidemiology and health services research using the Diagnosis Procedure Combination database in Japan. Asian Pacific J Dis Manag 2013; 7: 19–24.

9 Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173: 676–682.

10 Hugh-Jones P. Simple standard exercise test for measuring exertion dyspnöea. BMJ 1952; 1: 65–71.

11 Gosman-Hedstrom G, Svensson E. Parallel reliability of the functional independence measure and the Barthel ADL index. Disabil Rehabil 2000; 22: 702–715.

12 Yasunaga H. Introduction to applied statistics – chapter 1 propensity score analysis. Ann Clin Epidemiol 2020; 2: 33–37.

13 Li F, Thomas LE. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 2019; 188: 250–257.

14 Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc 2018; 113: 390–400.

15 Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28: 3083–3107.

16 Suzuki A, Kondoh Y, Brown KK, et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirology 2020; 25: 525–534.

17 Kolb M, Bondue B, Pesci A, et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27: 180071.

18 Naccache J-M, Jouneau S, Didier M, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2022; 10: 26–34.

19 Kondoh Y, Azuma A, Inoue Y, et al. Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis: a randomized, double-blind placebo-controlled trial. Am J Respir Crit Care Med 2020; 201: 1110–1119.

20 Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.

21 Kang J, Han M, Song JW. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Sci Rep 2020; 10: 15620.